

IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Please add new claims 28 and 29.

STATUS OF CLAIMS

Claim 1 (previously amended) A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding EIF2C1 (SEQ ID NO:3), wherein said compound specifically hybridizes with said nucleic acid molecule encoding EIF2C1 and inhibits the expression of EIF2C1.

Claim 2 (original) The compound of claim 1 which is an antisense oligonucleotide.

Claim 3 (canceled)

Claim 4 (original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

Claim 5 (original) The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

Claim 6 (original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

Claim 7 (original) The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

Claim 8 (original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Claim 9 (**original**) The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

Claim 10 (**original**) The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Claim 11 (**original**) A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding EIF2C1.

Claim 12 (**original**) A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 13 (**original**) The composition of claim 12 further comprising a colloidal dispersion system.

Claim 14 (**original**) The composition of claim 12 wherein the compound is an antisense oligonucleotide.

Claim 15 (**original**) A method of inhibiting the expression of EIF2C1 in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of EIF2C1 is inhibited.

Claims 16-19 (**canceled**)

Claim 20 (**previously amended**) A method of modulating the process of RNA-mediated interference (RNAi) in a cell or animal comprising administering to said cell or animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of EIF2C1 is inhibited.


Claim 21 (**previously added**) A method of interfering with a function of RNA in a cell comprising contacting a cell with an antisense compound capable of modulating an endogenous RNA-mediated interference pathway.

Claim 22 (**previously added**) The method of claim 21 wherein the function of RNA is translation of protein from said RNA.

Claim 23 (**previously added**) The method of claim 22 wherein the antisense compound is an antisense oligonucleotide.

Claim 24 (**previously added**) The method of claim 23 wherein the antisense oligonucleotide specifically hybridizes with a nucleic acid molecule encoding EIF2C1 and inhibits the expression of EIF2C1.

Claim 25 (**canceled**)

 Claim 26 (**previously added**) A method of inhibiting translation initiation in a cell comprising contacting a cell with an effective amount of the compound of claim 1 so that expression of a nucleic acid molecule encoding EIF2C1 is reduced and translation initiation is inhibited.

Claim 27 (**previously added**) A method of inhibiting translation initiation complex formation in a cell comprising contacting a cell with an effective amount of the compound of claim 1 so that expression of a nucleic acid molecule encoding EIF2C1 is reduced and translation initiation complex formation is inhibited.

Claim 28 (**new**) The method of any one of claims 15, 20, 21, 26 or 37 wherein said inhibition is at least 60%.

Claim 29 (**new**) The compound of claim 1 wherein said compound inhibits EIF2C1 expression by at least 60%.

Claim 30 (**new**) The method of claim 28 wherein said inhibition is at least 80%.

Claim 31 (**new**) The compound of claim 29 wherein said compound inhibits
EIF2C1 expression by at least 80%.
